Orphan Drug Designation Granted By FDA For Major Medical Company

Unicycive Therapeutics' UNI-494 Granted Orphan Drug Designation by FDA: A Leap Forward for Kidney Transplant Patients.

In a landmark development within the medical field, Unicycive Therapeutics (NASDAQ:UNCY) recently announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its drug candidate, UNI-494. This groundbreaking compound is being developed specifically for the prevention of Delayed Graft Function (DGF), a serious condition that can occur following kidney transplants. $Unicycive Therapeutics(UNCY.US)$

https://stockregion.app/p/orphan-drug-designation-granted-by

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

3257 Views

Comment

Stock Region

92Followers

0Following

221Visitors